Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient response to R-CHOP have not been e...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Jang, Geundoo, Yoon, Dok Hyun, Kim, Shin, Lee, Dae Ho, Lee, Sang-wook, Huh, Jooryung, Suh, Cheolwon
Формат: Artigo
Язык:Inglês
Опубликовано: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128890/
https://ncbi.nlm.nih.gov/pubmed/21747882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/kjh.2011.46.2.103
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы